Literature DB >> 35177843

Why does the Omicron sub-variant spread faster than the original?

Ewen Callaway.   

Abstract

Entities:  

Keywords:  SARS-CoV-2; Virology

Mesh：

Substances：

Year:  2022        PMID： 35177843     DOI： 10.1038/d41586-022-00471-2

Source DB:  PubMed          Journal:  Nature        ISSN： 0028-0836            Impact factor:   49.962


× No keyword cloud information.
  26 in total

Review 1.  Biological Properties of SARS-CoV-2 Variants: Epidemiological Impact and Clinical Consequences.

Authors:  Reem Hoteit; Hadi M Yassine
Journal:  Vaccines (Basel)       Date:  2022-06-09

Review 2.  Origin, virological features, immune evasion and intervention of SARS-CoV-2 Omicron sublineages.

Authors:  Shuai Xia; Lijue Wang; Yun Zhu; Lu Lu; Shibo Jiang
Journal:  Signal Transduct Target Ther       Date:  2022-07-19

Review 3.  Omicron BA.2 Lineage, the "Stealth" Variant: Is It Truly a Silent Epidemic? A Literature Review.

Authors:  Giorgio Tiecco; Samuele Storti; Stefania Arsuffi; Melania Degli Antoni; Emanuele Focà; Francesco Castelli; Eugenia Quiros-Roldan
Journal:  Int J Mol Sci       Date:  2022-06-30       Impact factor: 6.208

4.  Structural basis of human ACE2 higher binding affinity to currently circulating Omicron SARS-CoV-2 sub-variants BA.2 and BA.1.1.

Authors:  Linjie Li; Hanyi Liao; Yumin Meng; Weiwei Li; Pengcheng Han; Kefang Liu; Qing Wang; Dedong Li; Yanfang Zhang; Liang Wang; Zheng Fan; Yuqin Zhang; Qiyue Wang; Xin Zhao; Yeping Sun; Niu Huang; Jianxun Qi; George Fu Gao
Journal:  Cell       Date:  2022-06-16       Impact factor: 66.850

Review 5.  Review of COVID-19 testing and diagnostic methods.

Authors:  Olena Filchakova; Dina Dossym; Aisha Ilyas; Tamila Kuanysheva; Altynay Abdizhamil; Rostislav Bukasov
Journal:  Talanta       Date:  2022-03-31       Impact factor: 6.556

Review 6.  Passive Immunotherapy Against SARS-CoV-2: From Plasma-Based Therapy to Single Potent Antibodies in the Race to Stay Ahead of the Variants.

Authors:  William R Strohl; Zhiqiang Ku; Zhiqiang An; Stephen F Carroll; Bruce A Keyt; Lila M Strohl
Journal:  BioDrugs       Date:  2022-04-27       Impact factor: 7.744

7.  Heterologous immunization with inactivated vaccine followed by mRNA-booster elicits strong immunity against SARS-CoV-2 Omicron variant.

Authors:  Fanglei Zuo; Hassan Abolhassani; Likun Du; Antonio Piralla; Federico Bertoglio; Leire de Campos-Mata; Hui Wan; Maren Schubert; Irene Cassaniti; Yating Wang; Josè Camilla Sammartino; Rui Sun; Stelios Vlachiotis; Federica Bergami; Makiko Kumagai-Braesch; Juni Andréll; Zhaoxia Zhang; Yintong Xue; Esther Veronika Wenzel; Luigi Calzolai; Luca Varani; Nima Rezaei; Zahra Chavoshzadeh; Fausto Baldanti; Michael Hust; Lennart Hammarström; Harold Marcotte; Qiang Pan-Hammarström
Journal:  Nat Commun       Date:  2022-05-13       Impact factor: 17.694

Review 8.  Omicron: Understanding the Latest Variant of SARS-CoV-2 and Strategies for Tackling the Infection.

Authors:  Sreekanth Reddy Obireddy; Ujwala Guntakanti; Anitha Kowthalam; Subha Marata Chinna Subbarao; Wing-Fu Lai
Journal:  Chembiochem       Date:  2022-04-19       Impact factor: 3.461

Review 9.  COVID-19: Omicron - the latest, the least virulent, but probably not the last variant of concern of SARS-CoV-2.

Authors:  Harald Brüssow
Journal:  Microb Biotechnol       Date:  2022-04-20       Impact factor: 6.575

Review 10.  SARS-CoV-2 Omicron variant: recent progress and future perspectives.

Authors:  Yao Fan; Xiang Li; Lei Zhang; Shu Wan; Long Zhang; Fangfang Zhou
Journal:  Signal Transduct Target Ther       Date:  2022-04-28
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.